keyword
MENU ▼
Read by QxMD icon Read
search

Secukinumab

keyword
https://www.readbyqxmd.com/read/29785816/ixekizumab-or-secukinumab-in-psoriasis-what-difference-does-it-make
#1
C Paul
No abstract text is available yet for this article.
May 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29767491/dermatophytosis-in-a-psoriatic-patient-treated-with-secukinumab-an-underrated-adverse-effect
#2
Camilla Loi, Annalisa Patrizi, Andrea Sechi, Federico Tartari, Michela Magnano, Federico Bardazzi
No abstract text is available yet for this article.
August 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29750443/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-update-short-version-part-1-systemic-treatment
#3
Alexander Nast, Lasse Amelunxen, Matthias Augustin, Wolf-Henning Boehncke, Corinna Dressler, Matthew Gaskins, Peter Härle, Bernd Hoffstadt, Joachim Klaus, Joachim Koza, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Berthold Rzany, Martin Schlaeger, Gerhard Schmid-Ott, Michael Sebastian, Ralph von Kiedrowski, Tobias Weberschock
The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process. The first section of this short version of the guideline covers systemic treatment options considered relevant by the expert panel and approved in Germany at the time of the consensus conference (acitretin, adalimumab, apremilast, cyclosporine, etanercept, fumaric acid esters, infliximab, methotrexate, secukinumab and ustekinumab)...
May 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29746636/emergence-of-inflammatory-bowel-disease-during-treatment-with-secukinumab
#4
María José Fobelo Lozano, Reyes Serrano Giménez, Manuel Castro Fernández
Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess its efficacy in patients with Crohn disease have been published. On the other hand, the drug fact sheet states that secukinumab should be used with caution in patients with inflammatoy bowel disease...
May 9, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29733240/drug-survival-of-secukinumab-for-psoriasis-in-a-real-world-setting
#5
Erica B Lee, Mina Amin, Alexander Egeberg, Jashin J Wu
No abstract text is available yet for this article.
May 7, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29729105/cost-effectiveness-of-secukinumab-as-first-biologic-treatment-compared-with-other-biologics-for-moderate-to-severe-psoriasis-in-germany
#6
Matthias Augustin, Doreen McBride, Isabelle Gilloteau, Caitriona O'Neill, Katja Neidhardt, Christopher N Graham
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has demonstrated strong and sustained efficacy in adults with moderate to severe psoriasis in clinical trials. OBJECTIVE: This analysis compared the cost per responder of secukinumab as first biologic treatment of moderate to severe psoriasis, with adalimumab, infliximab, etanercept, and ustekinumab in Germany. METHODS: A 52-week decision-tree model was developed...
May 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29717037/the-effect-of-biologic-and-targeted-synthetic-drugs-on-work-and-productivity-related-outcomes-for-patients-with-psoriatic-arthritis-a-systematic-review
#7
Nicolas Iragorri, Mark Hofmeister, Eldon Spackman, Glen S Hazlewood
OBJECTIVE: To systematically review the effects of biologic therapies for psoriatic arthritis [secukinumab, ustekinumab, adalimumab, etanercept, certolizumab pegol (CZP), apremilast, golimumab (GOL), or infliximab (IFX)] on work productivity. METHODS: A systematic review of Medline, EMBASE, CENTRAL, and ClinicalTrials.gov was conducted to identify randomized controlled trials reporting on work productivity outcomes at the end of the placebo-controlled double-blind period...
May 1, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29704432/secukinumab-shows-high-efficacy-irrespective-of-hla-cw6-status-in-patients-with-moderate-to-severe-plaque-type-psoriasis-supreme-study
#8
A Costanzo, L Bianchi, M L Flori, G Malara, L Stingeni, M Bartezaghi, L Carraro, G Castellino
BACKGROUND: Understanding genetic variations is important in predicting the treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for the treatment of psoriasis. Limited data are available for the efficacy of secukinumab in relation to genetic markers. OBJECTIVE: To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-to-severe chronic plaque-type psoriasis...
April 28, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29693056/secukinumab-dose-optimization-in-adult-psoriasis-patients-a-retrospective-multicenter-case-series
#9
Michelle Phung, Jorge R Georgakopoulos, Arvin Ighani, Lyne Giroux, Jensen Yeung
No abstract text is available yet for this article.
May 2018: JAAD Case Reports
https://www.readbyqxmd.com/read/29689643/il-17a-promotes-the-invasion-metastasis-cascade-via-the-akt-pathway-in-hepatocellular-carcinoma
#10
Qing-Guo Xu, Jian Yu, Xing-Gang Guo, Guo-Jun Hou, Sheng-Xian Yuan, Yuan Yang, Yun Yang, Hui Liu, Ze-Ya Pan, Fu Yang, Fang-Ming Gu, Wei-Ping Zhou
We previously demonstrated that interleukin-17A (IL-17A) is associated with the progression of hepatocellular carcinoma (HCC). However, its role in the invasion-metastasis cascade of HCC and the efficacy of IL-17A-targeting therapeutics in HCC remain largely unknown. In this study, we found that IL-17A promoted intrahepatic and pulmonary metastasis of HCC cells in an orthotopic implant model. Moreover, our results showed that IL-17A induced epithelial-mesenchymal transition (EMT) and promoted HCC cell colonization in vitro and in vivo, and the role of IL-17A in invasion-metastasis was dependent on activation of the AKT pathway...
April 24, 2018: Molecular Oncology
https://www.readbyqxmd.com/read/29666723/a-challenging-case-of-severe-ulcerative-colitis-following-the-initiation-of-secukinumab-for-ankylosing-spondylitis
#11
Dean Ehrlich, Nimah Jamaluddin, Joseph Pisegna, David Padua
Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent...
2018: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/29658383/comparison-of-the-cost-effectiveness-of-biologic-drugs-used-for-moderate-to-severe-psoriasis-treatment-in-the-united-states
#12
Jashin J Wu, Steven R Feldman, Shipra Rastogi, Brandy Menges, Melissa Lingohr-Smith, Jay Lin
PURPOSE: To compare the cost-effectiveness of the newly approved biologic drug, brodalumab, with other commonly used biologics for the treatment of moderate-to-severe psoriasis in the U.S. METHODS: An economic model was constructed in Excel to compare average costs to achieve Psoriasis Area and Severity Index (PASI) 75, 90, and 100 among moderate-to-severe psoriasis patients treated with biologics. Total annual costs to health plans associated with treatment with 5 different biologics were estimated and cost-effectiveness compared using the estimated average cost per PASI 75, PASI 90, and PASI 100...
April 16, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29644062/granulomatous-interstitial-nephritis-secondary-to-adalimumab-therapy
#13
Vicki Sandys, Brona Moloney, Louise Lane, Junaid Qazi, Brendan Doyle, Maurice Barry, Sean Leavey, Peter Conlon
Tumour necrosis factor α (TNF-α) inhibitors are frequently used for the treatment of immune-mediated diseases. Conversely, cytokine therapy has the potential to paradoxically induce autoimmunity. A number of case reports have emerged concerning sarcoid-like granulomatosis secondary to TNF-α therapy, an adverse effect that typically affects the pulmonary and cutaneous systems. Granulomatous interstitial nephritis (GIN) is a relatively unknown, relatively under-reported consequence of adalimumab therapy that can have important clinical implications...
April 2018: Clinical Kidney Journal
https://www.readbyqxmd.com/read/29619856/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-psoriasis-a-network-meta-analysis
#14
April W Armstrong, Keith A Betts, James E Signorovitch, Murali Sundaram, Junlong Li, Arijit X Ganguli, Eric Q Wu
BACKGROUND: The clinical benefits of biologic therapies for moderate-to-severe psoriasis are well established, but wide variations exist in patient response. OBJECTIVES: To determine the number needed to treat (NNT) to achieve a 75% and 90% reduction in the Psoriasis Area and Severity Index (PASI-75/90) with FDA-approved agents and evaluate the incremental cost per PASI-75 or PASI-90 responder. METHODS: The relative probabilities of achieving PASI-75 and PASI-90, as well as NNTs, were estimated using a network meta-analysis...
April 23, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29618121/precision-medicine-using-different-biological-dmards-based-on-characteristic-phenotypes-of-peripheral-t-helper-cells-in-psoriatic-arthritis
#15
Ippei Miyagawa, Shingo Nakayamada, Kazuhisa Nakano, Satoshi Kubo, Shigeru Iwata, Yusuke Miyazaki, Maiko Yoshikawa, Hiroko Yoshinari, Yoshiya Tanaka
Objectives: We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA. Methods: Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral helper T cells on 8-colour flow cytometry. The efficacies of this strategic treatment and the standard treatment administered to the other 38 patients were evaluated at 6 months...
April 2, 2018: Rheumatology
https://www.readbyqxmd.com/read/29605841/secukinumab-versus-adalimumab-for-psoriatic-arthritis-comparative-effectiveness-up-to-48-weeks-using-a-matching-adjusted-indirect-comparison
#16
Peter Nash, Iain B McInnes, Philip J Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, Steffen M Jugl
INTRODUCTION: Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. METHODS: Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs...
March 31, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29596876/successful-treatment-of-severe-psoriasis-relapse-with-secukinumab-il17-a-inhibitor-after-abrupt-brodalumab-il17-receptor-inhibitor-discontinuation-a-retrospective-study-evaluating-long-term-efficacy-and-safety
#17
Abdallah Khemis, Awatef Kelati, Henri Montaudié, Jean-Philippe Lacour, Thierry Passeron
No abstract text is available yet for this article.
March 26, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29551008/author-correction-secukinumab-demonstrates-significantly-lower-immunogenicity-potential-compared-to-ixekizumab
#18
Sebastian Spindeldreher, Bernard Maillère, Evelyne Correia, Maxime Tenon, Anette Karle, Philip Jarvis, Frank Kolbinger
In the original publication, information regarding "ustekinumab" was incorrectly published under the Methods section. The correct information in the section "Antibodies and Control Protein" should be "(secukinumab, 150 mg/mL; ixekizumab, 90 mg/mL; adalimumab, 50 mg/mL; ustekinumab 90 mg/ml)". Infliximab, which is mentioned in that section, was not used in the study.
March 17, 2018: Dermatology and Therapy
https://www.readbyqxmd.com/read/29550766/secukinumab-improves-active-psoriatic-arthritis-symptoms-and-inhibits-radiographic-progression-primary-results-from-the-randomised-double-blind-phase-iii-future-5-study
#19
Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser, Aimee Readie, Luminita Pricop, Ken Abrams
OBJECTIVES: To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA). METHODS: Adults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 150 mg with loading dose (LD), 150 mg without LD or placebo. All groups received secukinumab or placebo at baseline, weeks 1, 2 and 3 and then every 4 weeks from week 4...
June 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29549597/biosimilar-drugs-for-psoriasis-principles-present-and-near-future
#20
REVIEW
Jose-Manuel Carrascosa, Ira Jacobs, Danielle Petersel, Robert Strohal
Psoriasis is a chronic, inflammatory, lifelong disease with a high prevalence (afflicting approximately 1-5% of the population worldwide) and is associated with significant morbidity. The introduction of biologic therapies has improved the management of this disease. Multiple biologic medicines that block cytokine signaling, including tumor necrosis factor (TNF) antagonists (adalimumab, etanercept, and infliximab) and inhibitors of interleukin (IL)-17 (brodalumab, ixekizumab, and secukinumab), IL-23 (guselkumab), or IL-12/23 (ustekinumab), are approved for the treatment of psoriasis...
March 16, 2018: Dermatology and Therapy
keyword
keyword
30575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"